Research Pulse — 2026-08-26 | Brown Biotech

# Research Pulse — 2026-08-26
_Generated 2026-08-26 07:34 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 8월 26일 (수요일) · Translating(전이 Day)**

8/26(전이)→8/20(Expanding)→8/19(Diversifying)→8/18(Converging)→8/17(Standardizing)→8/16(Industrializing)→...→7/14(가속). Expanding(8/20)된 기술들이 **실험실 → 임상/산업으로의 전이(Translating) 단계에 진입하는 날** — prime editing first-in-human functional restoration + safety profile 확인(Lushington Molecular Therapy 2026), non-viral CRISPR carriers 136 trials·36 in vivo로 전환 확인(Lummerstorfer Drug Delivery 2026), pharma 2026년 AI platforms 대규모 딜 급증 확인(Lin GEN Biotechnology 2026), ROCKET이 AlphaFold2+실험 데이터 통합으로 cryo-EM/ET/X-ray 자동 모델링 달성 확인(Fadini Nature Methods 2026), scFM interpretability에서 attention이 co-expression만 포착 + regulatory signal 아닌 문제 확인(Kendiukhov ArXiv 2026), NfL biomarker로 CALD gene therapy 예후 예측 50% 감소 확인(Lund Molecular Therapy Advances 2026), 12개 암종 373 samples에서 56 LCPs+13 niches로 TSME 체계적 분석 확인(Li Cell Reports Medicine 2026)이 동시에 진행된다.

Translating은 Expanding의 다음 단계다. 오늘 6개 전선은跨영역 확산된 기술들이 **임상/산업적 전이 조건을 충족하는 날**이다.

*출처: [Lushington PE First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Lummerstorfer Non-Viral CRISPR Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/), [Lin Pharma AI Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Fadini ROCKET AlphaFold Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/), [Kendiukhov scFM Interpretability ArXiv 2026](https://consensus.app/papers/details/d53d25b7c73855978a42e9832c85eb8c/), [Lund NfL CALD Gene Therapy Molecular Therapy Advances 2026](https://consensus.app/papers/details/35746e04ff4a58eb8b8c03fcf3735d62/), [Li Pan-Cancer TSME Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#TranslatingDay #PE #FirstInHuman #Lushington #MolecularTherapy #Lummerstorfer #NonViral #CRISPR #Lin #PharmaAI #Deals2026 #Fadini #ROCKET #AlphaFold #NatureMethods #Kendiukhov #scFM #Interpretability #Attention #Lund #NfL #CALD #GeneTherapy #Biomarker #Li #TSME #CellReportsMedicine #Translating #Expanding #ClinicalTranslation #InVivo #NonViralVectors*

---

### Post 2: CRISPR & Gene Editing — PE First-in-Human Functional Restoration + Non-Viral 136 Trials

🧪 **[CRISPR/Gene Editing] PE first-in-human trial에서 functional restoration + promising safety profile 확인(Lushington Molecular Therapy 2026) + Non-viral CRISPR carriers 136 trials·36 in vivo delivery로 전환 확인(Lummerstorfer Drug Delivery 2026) + PE1→PE7 technological evolution + delivery strategies 체계적 review 확인(Jong BMB Reports 2026): prime editing의 임상 전이 동시 확인**

CRISPR 유전자 편집 기술의**임상 전이**가 출처에서 동시에 확인된다[1][2][3].

**PE First-in-Human: Functional Restoration + Promising Safety Profile[1]**
Caleb Lushington et al.(Molecular Therapy 2026)의 review는 PE의 first-in-human study를 분석한다. **PE의 장점**: double-strand breaks 불필요, exogenous donor DNA 불필요, Cas9 nickase + reverse transcriptase fusion으로 작동. **PE 진화**: PE1→PE7로 efficiency 향상, editable target range 확대, large genomic regions 교정, in vivo delivery 기술 개발. **First-in-human 성과**: functional restoration 확인 + promising safety profile to date. **향후 도전**: efficiency·delivery·safety — broader clinical impact를 위한 과제. 핵심: Prime editing first-in-human functional restoration 확인 — 임상 전이里程碑 달성.

**Non-Viral CRISPR Carriers: 136 Trials · 36 In Vivo · Non-Viral Shift[2]**
Maria Lummerstorfer et al.(Drug Delivery 2026)의 review는 in vivo CRISPR therapies의 임상 시험 현황을 분석한다. **136 CRISPR trials 진행 중**(2025년 12월 기준). **36건 in vivo delivery** — viral vectors dominance에서 **non-viral vectors로의 명확한 전환** 확인. **Non-viral 우위**: hit-and-run fashion으로 off-target risk↓, transient delivery로 lasting therapeutic effects 가능. **Clinically employed technologies**: nanoparticles, lipid-based systems 포함. **미래 기회와 도전**: key challenges associated with CRISPR delivery. 핵심: Non-viral CRISPR carriers 136 trials + 36 in vivo로 전환 확인 — 전달 기술 전이.

**Prime Editing Technological Evolution: PE1→PE7 + Delivery Strategies[3]**
U. Jong et al.(BMB Reports 2026)의 review는 prime editing의 방법론적 진화를 종합한다. **PE mechanism**: Cas9 nickase + reverse transcriptase fusion + pegRNA. **기술 진화**: PE1→PE7로 editing efficiency 향상, editable target range 확대, large genomic regions 교정 가능. **전달 플랫폼**: nanoparticles, split viral systems 등 in vivo delivery 기술 발전. **치료 적용**: 다양한 질병 모델에서 preclinical 성과 축적. 핵심: Prime editing PE1→PE7 technological evolution + delivery strategies 체계적 review — 임상 전이 기반 확립.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Janjuha Nature Biomedical Engineering**으로 **ISS로 gene editing spatial profiling跨영역 확산**을, **Froechlich Molecular Therapy**으로 **mRNA/LNP vaccine de-targeting으로 tissue competency mapping 확산**을, **Tálas Science Translational Medicine**으로 **RNA-LNP PE7로 CTLN1 치료 가능성 확산**을 제시했다면, 오늘은 **Lushington Molecular Therapy**으로 **PE first-in-human functional restoration + safety profile**을(임상 전이), **Lummerstorfer Drug Delivery**으로 **136 trials + 36 in vivo + non-viral vectors 전환**을(산업 전이), **Jong BMB Reports**으로 **PE1→PE7 technological evolution + delivery strategies**를(기술적 전이 기반) 동시에 제시한다. Expanding(8/20) → 임상/산업 전이 Translating(8/26).

실무 함의: 유전자 치료 전달 기술팀에서 Lummerstorfer et al.의 non-viral vectors 전환 분석을 참조하여 delivery strategy를 수립해야 한다.

*출처: [Lushington PE First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Lummerstorfer Non-Viral CRISPR Carriers Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/), [Jong Prime Editing Evolution BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/)*

*#CRISPR #PrimeEditing #Lushington #MolecularTherapy #FirstInHuman #FunctionalRestoration #SafetyProfile #Lummerstorfer #DrugDelivery #NonViral #InVivo #136Trials #Jong #BMBReports #PE1 #PE7 #Evolution #Delivery #Nanoparticles #LipidBased #TranslatingDay #ClinicalTranslation #HitAndRun #OffTarget #ViralToNonViral #GeneEditing*

---

### Post 3: AI 신약 — Pharma 2026 AI Deals 급증 + AI Drug Discovery 전이 현실

💊 **[AI 신약] Pharma 2026년 AI platforms 대규모 딜 급증 확인(Lin GEN Biotechnology 2026) + AI drug discovery transforming pharmaceutical innovation 종합 확인(Ali Drug Development Research 2026) + AI drug discovery의 data quality 한계와perimental validation 필수 확인(Seyhan Critical Reviews Oncology/Hematology 2026): AI drug discovery의 산업 전이 동시 확인**

AI-Driven Drug Discovery의**산업 전이**가 출처에서 동시에 확인된다[4][5][6].

**Pharma Bets Big on AI: 2026 Deals 급증[4]**
Fay Lin(GEN Biotechnology 2026)의 연구는 2026년 pharma의 AI platform 대규모 딜을 분석한다. **2026년 급증**: pharma companies가 AI platforms에 대규모 투자 결정. **적용 영역**: drug discovery acceleration, development timelines 단축, costs 절감. **파트너십 모델**: AI developers와 pharmaceutical industries 사이 collaborative models. **AI의 역할**: "lab partner"로서의 기능 확대. 핵심: Pharma 2026년 AI platforms 대규모 딜 급증 — AI drug discovery 산업 전이 가속화.

**AI Drug Discovery Transforming Pharmaceutical Innovation[5]**
M. Ali et al.(Drug Development Research 2026)의 review는 AI의 drug discovery pipeline 전반 적용을 분석한다. **AI 적용 영역**: target identification, hit finding, lead optimization, drug repurposing, toxicity prediction, pharmacokinetics forecasting. **AI-driven insilico platforms**: early-stage predictability 향상, late-stage attrition↓. **Collaborative models**: AI developers + pharma industries 필수. **도전 과제**: algorithmic transparency, data quality, interoperability, regulatory acceptance. 핵심: AI drug discovery transforming pharmaceutical innovation — pipeline 전반 적용 전이.

**AI Drug Discovery의 한계: Data Quality + Experimental Validation 필수[6]**
A. Seyhan et al.(Critical Reviews in Oncology/Hematology 2026)의 review는 AI drug discovery의 제약을 분석한다. **AI의 한계**: vast chemical/biological space exploration 가속화하나 quality of upstream data에 의해 엄격히 제한. **AlphaFold·MoleR·PocketCrafter 등 플랫폼**: 적용 범위 확대. **FDA 승인 AI-enabled devices**: 다수 승인 — 그러나 **fully AI-discovered and AI-designed drug는 아직 0개**. **진입한 AI candidate들**: 임상 개발 진행 중. **핵심 제약**: high-quality multimodal data 접근, robust regulatory/ethical frameworks 필요. 핵심: AI drug discovery data quality 한계 확인 — experimental validation 필수 인식 강화.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Zhang Drug Development Research**으로 **DrugCLIP contrastive learning으로 genome-wide screening ultrafast 적용**을, **Raghupathi Health Information Science Systems**으로 **4Vs framework의 veracity·validity·viability로 확장**을, **de Oliveira Teixeira Journal Computer-Aided Molecular Design**으로 **AlphaFold structures antibiotic resistance로 확산**을 제시했다면, 오늘은 **Lin GEN Biotechnology**으로 **pharma 2026년 AI platforms 대규모 딜 급증**을(산업 전이 가속), **Ali Drug Development Research**으로 **AI drug discovery pipeline 전반 적용 종합**을(전환), **Seyhan Critical Reviews**으로 **data quality 한계 + fully AI-designed drug 0개 현실**을(전이 한계) 동시에 제시한다. Expanding(8/20) → 산업 전이 + 한계 인식 Translating(8/26).

실무 함의: AI drug discovery 협업팀에서 Lin et al.의 2026 딜 급증 분석을 참조하여 partnership strategy를 수립해야 한다.

*출처: [Lin Pharma AI Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Ali AI Drug Discovery Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)*

*#AI #DrugDiscovery #Lin #GENG biotechnology #PharmaAI #Deals2026 #Ali #DrugDevelopmentResearch #PharmaceuticalInnovation #Seyhan #CriticalReviews #OncologyHematology #DataQuality #Validation #AlphaFold #MoleR #PocketCrafter #TranslatingDay #IndustrialTranslation #CollaborativeModels #AIPlatforms #RegulatoryAcceptance #ZeroAIApprovedDrugs*

---

### Post 4: 단백질 AI — ROCKET AlphaFold2 + 실험 데이터 통합과 AlphaFind v2

🔬 **[단백질 AI] ROCKET이 AlphaFold2+실험 데이터(cryo-EM/ET/X-ray) 통합으로 자동 모델링 달성 확인(Fadini Nature Methods 2026) + AlphaFind v2로 AlphaFold DB에서 TED domains까지 구조 유사성 검색 확인(Slanináková Nucleic Acids Research 2026) + AlphaFold AI-driven protein structure prediction 종합 review 확인(Yin Frontiers Molecular Biosciences 2026): 단백질 구조 AI의 실험 데이터 전이 동시 확인**

단백질 AI의**실험 데이터 전이**가 출처에서 동시에 확인된다[7][8][9].

**ROCKET: AlphaFold2 + Cryo-EM/ET/X-ray 통합 자동 모델링[7]**
A. Fadini et al.(Nature Methods 2026)의 연구는 ROCKET을 제시한다. **AlphaFold2의 한계**: side-chain packing, condition-dependent conformational changes, biomolecular interactions 모델링困难 — limited high-quality training data. **ROCKET의 혁신**: cryo-EM, cryo-ET, X-ray crystallography 데이터를 AlphaFold2 prediction에 직접 통합. **방법**: coevolutionary embeddings 공간에서 구조 최적화 — Cartesian coordinates 아님. **成果**: AlphaFold2 alone에서 불가능한 biologically meaningful structural variation 포착. **강점**: scalable, automated model building without retraining. **범용 프레임워크**: experimental observables + biomolecular ML 통합. 핵심: ROCKET이 AlphaFold2 + 실험 데이터 통합으로 자동 모델링 달성 — computational-experimental 전이.

**AlphaFind v2: TED Domains 구조 유사성 검색 + AlphaFold DB[8]**
Terézia Slanináková et al.(Nucleic Acids Research 2026)의 연구는 AlphaFind v2를 제시한다. **AlphaFold Database**: large-scale protein structure collections. **현재 bottleneck**: 3D structure comparison at scale computationally demanding. **AlphaFind v2 해결책**: fast pre-filtering via state-of-the-art protein embeddings + US-align refinement. **검색 모드**: (1) full protein chains, (2) pLDDT-aware region-restricted, (3) TED database domains, (4) multidomain search. **특징**: organism/CATH label 필터, experimental structures 매칭. **접근**: https://alphafind.ics.muni.cz/. 핵심: AlphaFind v2로 AlphaFold DB에서 TED domains까지 대규모 구조 유사성 검색 — 구조数据库 전이.

**AI-Driven Protein Structure Prediction: 종합 Review[9]**
Tianxiang Yin et al.(Frontiers in Molecular Biosciences 2026)의 review는 protein structure prediction의 AI 방법을 종합한다. **배경**: X-ray, NMR, cryo-EM의 한계 — low throughput, high cost, demanding sample preparation. **AlphaFold3, RoseTTAFold**: near-experimental accuracy 달성. **ESMFold**: 속도와 scalability 향상. **적용**: drug discovery, enzyme engineering, disease research. **도전 과제**: current challenges and future directions. 핵심: AI-driven protein structure prediction 종합 review — 단백질 구조 AI의 전이 상태 종합.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **de Oliveira Teixeira Journal Computer-Aided Molecular Design**으로 **AlphaFold structures가 antibiotic resistance therapeutic target discovery로 확산**을, **Tortolani Biochemical Pharmacology**으로 **GPR18 AlphaFold modeling으로 neuroinflammatory disorders 치료 표적**을, **Dhir RSC Advances**으로 **AI drug design workflow 全단계 포괄적 종합**을 제시했다면, 오늘은 **Fadini Nature Methods**으로 **ROCKET으로 AlphaFold2 + 실험 데이터 통합 자동 모델링**을(Computational-experimental 전이), **Slanináková Nucleic Acids Research**으로 **AlphaFind v2로 AlphaFold DB + TED domains 대규모 검색**을(데이터베이스 전이), **Yin Frontiers**으로 **protein structure prediction 종합 review**를(전체 분야 전이 현황) 동시에 제시한다. Expanding(8/20) → computational-experimental Translating(8/26).

실무 함의: 전산단백질 설계팀에서 Fadini et al.의 ROCKET 접근법을 분석하여 computational-experimental integration strategy를 수립해야 한다.

*출처: [Fadini ROCKET AlphaFold Cryo-EM Integration Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/), [Slanináková AlphaFind v2 Nucleic Acids Research 2026](https://consensus.app/papers/details/ab20081f847c53918401f1728031bb64/), [Yin Protein Structure AI Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)*

*#ProteinAI #AlphaFold #ROCKET #Fadini #NatureMethods #CryoEM #CryoET #Xray #AlphaFind #Slanináková #NAR #TED #CATH #StructuralSimilarity #Yin #Frontiers #MolecularBiosciences #ProteinStructure #DrugDiscovery #EnzymeEngineering #TranslatingDay #ComputationalExperimental #Integration #AutomatedModeling #CoevolutionaryEmbeddings*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — scFM Interpretability Attentions Failure + Learnability 평가

🬬 **[Single-Cell Multi-Omics Foundation Model] scFM attention patterns이 co-expression만 포착 + regulatory signal 아닌 문제 확인(Kendiukhov ArXiv 2026) + scFM learnability에서 scaling laws 한계 확인 — perturbation prediction에서 limited gains(Yan BMC Genomics 2026) + scFM perturbation·causal inference 종합 review 확인(Dimitrov Nature Reviews Genetics 2026): foundation model의 전이 한계 동시 확인**

Single-Cell Foundation Model의**전이 한계**가 출처에서 동시에 확인된다[10][11][12].

**scFM Attention Patterns: Co-Expression만 포착 · Regulatory Signal 아님[10]**
Ihor Kendiukhov(ArXiv 2026)의 연구는 scFM mechanistic interpretability를 체계적으로 평가한다. **평가 프레임워크**: 37 analyses, 153 statistical tests, 4 cell types, 2 perturbation modalities. **대상 모델**: scGPT, Geneformer. **발견**: attention patterns가 biological information encode — early layers에서 protein-protein interactions, late layers에서 transcriptional regulation. **그러나**: attention structure가 perturbation prediction에 incremental value 없음. **대조**: trivial gene-level baselines가 attention보다 superior(AUROC 0.81-0.88 vs 0.70). **Pairwise edge scores**: zero predictive contribution. **Causal ablation**: regulatory heads 제거해도 degradation 없음. **Cell-State Stratified Interpretability(CSSI)**: attention-specific scaling failure 해결, GRN recovery 1.85x 향상. 핵심: scFM attention이 co-expression만 포착 — regulatory signal 아님 → perturbation prediction 한계 확인.

**scFM Learnability: Scaling Laws 한계 + Perturbation Prediction에서 Limited Gains[11]**
Yuhai Yan et al.(BMC Genomics 2026)의 연구는 scFMs의 learnability를 평가한다. **대상 모델**: Geneformer, scGPT. **cell type annotation**: large-scale pretraining substantial advantages 제공. **perturbation prediction**: limited gains — benefits strongly task-dependent. **"Bigger is better" paradigm 도전**: model size 증가가 performance 개선 guarantee하지 않음 — 오히려 detrimental 가능. **분석 결과**: perturbation prediction에서 scFMs가 simple summary statistics 이상의 것을 capture하지 못할 가능성. **권장**: task-specific architectures + biologically-informed priors로 방향 전환 필요. 핵심: scFM scaling laws 한계 확인 — perturbation prediction에서 limited gains.

**scFM Perturbation · Causal Inference · Mechanistic Discovery 종합 Review[12]**
Daniel Dimitrov et al.(Nature Reviews Genetics 2026)의 review는 single-cell 분석의 패러다임 전환을 분석한다. **전환**: descriptive atlasing → causal effects and mechanistic relationships 추론. **방법론**: representation learning, causal inference, mechanistic discovery, disentanglement, population tracing. ** ontology 제안**: practitioners를 위한 unified ontology — 방법론 선택 guidance. **기술 설명**: 각 방법론의 technical descriptions 제공. **미래 방향**: underexplored data properties로 computational directions 제시. 핵심: scFM perturbation과 causal inference 방법론 종합 review — 전이 과제 인식.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Kendiukhov Computational Biology Chemistry**으로 **foundation model perturbation adversarial validation framework**를, **Abir NAR Genomics Bioinformatics**으로 **CFM-GP conditional flow matching으로 gene perturbation prediction 확산**을, **Fan Synthetic Systems Biotechnology**으로 **scYeast biological-knowledge-guided model로 yeast 영역 확산**을 제시했다면, 오늘은 **Kendiukhov ArXiv**으로 **attention patterns가 co-expression만 포착 · regulatory signal 아닌 문제**를(전이 한계), **Yan BMC Genomics**으로 **scaling laws 한계 + perturbation prediction limited gains**를(모델 한계), **Dimitrov Nature Reviews Genetics**으로 **perturbation·causal inference 종합 review**를(방법론 전이 한계) 동시에 제시한다. Expanding(8/20) → 전이 한계 인식 강화 Translating(8/26).

실무 함의: 단일세포 연구팀에서 Kendiukhov et al.의 attention failure 분석을 참조하여 scFM 적용 전제 조건을 재검토해야 한다.

*출처: [Kendiukhov scFM Attention Interpretability ArXiv 2026](https://consensus.app/papers/details/d53d25b7c73855978a42e9832c85eb8c/), [Yan scFM Learnability BMC Genomics 2026](https://consensus.app/papers/details/db23619e10075c0eb0957368f25ba7de/), [Dimitrov scFM Perturbation Causal Inference Nature Reviews Genetics 2026](https://consensus.app/papers/details/4c9a5a9396a85b9797d6e1f0ecd4286b/)*

*#SingleCell #FoundationModel #scFM #Kendiukhov #ArXiv #Attention #CoExpression #RegulatorySignal #Yan #BMCGenomics #Learnability #ScalingLaws #Dimitrov #NatureReviewsGenetics #Perturbation #CausalInference #Mechanistic #TranslatingDay #Interpretability #PerturbationPrediction #CSSI #GRN #TaskSpecific #BiologicallyInformed*

---

### Post 6: FDA/규제 — FDA 1998-2025 Gene Therapy Approvals 분석과 CGT Quality Bottleneck

📋 **[FDA/규제] FDA gene therapy approvals 1998-2025 분석으로 platform-aligned risk-based initiatives 도입 확인(Oo J Clinical Pharmacology 2026) + CGT approved products quality bottlenecks 분석 — comparability·potency assay·specifications 문제 확인(Iglesias-López Therapeutic Innovation Regulatory Science 2026) + NfL biomarker로 CALD gene therapy 예후 예측 확인 — 50% 감소(Lund Molecular Therapy Advances 2026): FDA/규제의 전이 분석 동시 확인**

FDA/규제의**전이 분석**이 출처에서 동시에 확인된다[13][14][15].

**FDA Gene Therapy Approvals 1998-2025: Platform-Aligned Initiatives 도입[13]**
C. Oo et al.(J Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals를 종합 분석한다. **1998-2025 현황**: approvals began slowly, concentrated in early modalities → recent years marked acceleration across RNA-based agents, viral/non-viral in vivo platforms, ex vivo genetically modified cell therapies. **FDA platform-aligned initiatives**: plausible mechanism framework, CMC flexibility initiative, advanced manufacturing technologies program. **현재 도전**: high upfront costs, manufacturing complexity, payer constraints — sustainable development and access models 필요. **AI/ML analytics**: dose selection, safety evaluation, durability prediction 지원 확대. 핵심: FDA gene therapy approvals 1998-2025 분석으로 platform-aligned risk-based initiatives 도입 — 규제 전이 체계 확립.

**CGT Quality Bottlenecks: Manufacturing Comparability · Potency Assay · Specifications[14]**
C. Iglesias-López et al.(Therapeutic Innovation & Regulatory Science 2026)의 연구는 EU/US CGT approvals의 quality issues를 분석한다. **14개 CGT approved**(12 US, 11 EU). **All orphan designation**, >80% expedited development pathways. **Quality objections**: manufacturing comparability, potency assay validation, specifications, stability data. **FDA vs EMA**: FDA는 data-driven approach, EMA는 broader science-based view + continuous improvement. **핵심 문제**: regulatory support mechanisms가 dossiers quality 향상에 일관되게 translate되지 않음. **권장**: quality-by-design principles early integration, comprehensive comparability assessments, validated potency assays. 핵심: CGT quality bottlenecks 분석 — regulatory submissions 강화를 위한 전이 과제 확립.

**NfL Biomarker: CALD Gene Therapy 예후 예측 — 50% 감소[15]**
T.C. Lund et al.(Molecular Therapy Advances 2026)의 연구는 CALD gene therapy 후 CSF/plasma biomarker dynamics를 분석한다. **대상**: gene therapy for cerebral adrenoleukodystrophy(CALD). **NfL(Neurofilament light chain)**: pre-GT plasma NfL이 MRI Loes score와 강하게 상관(R²=0.8132). **50% 감소**: 환자들에서 gene therapy 후 2년 시점 median reduction 50% 확인. **6개월 NfL이 12개월 disease progression 예측**: univariate(p=0.0003), multivariate(p=0.0304). **GFAP**: neuroinflammatory marker도 변화 관찰. **첫 번째 보고**: NfL이 CALD gene therapy에서 prognostic biomarker로 유효성 최초 확인. 핵심: NfL biomarker로 CALD gene therapy 예후 예측 — biomarker-driven regulatory translation.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Staton Cancer Biology Therapy**으로 **CAPItello-281 biomarker-guided FDA approval**을, **Morimoto Regenerative Therapy**으로 **ALS three converging approaches 구체화**를, **Del Toro Runzer Bioactive Materials**으로 **BMP-7 mRNA 골 재생 적용**을 제시했다면, 오늘은 **Oo J Clinical Pharmacology**으로 **FDA 1998-2025 gene therapy approvals 분석 + platform-aligned initiatives**를(규제 체계 전이), **Iglesias-López Therapeutic Innovation**으로 **CGT quality bottlenecks로 regulatory submissions 강화 과제**를(품질 전이 한계), **Lund Molecular Therapy Advances**으로 **NfL biomarker CALD gene therapy 예후 예측 50% 감소**를(biomarker-driven translation) 동시에 제시한다. Expanding(8/20) → 규제 체계 + 품질 + biomarker 전이 Translating(8/26).

실무 함의: 규제 기획팀에서 Oo et al.의 FDA approvals 분석을 참조하여 gene therapy regulatory strategy를 수립해야 한다.

*출처: [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Iglesias-López CGT Quality Therapeutic Innovation Regulatory Science 2026](https://consensus.app/papers/details/49b52f00e1d45031af864f85aeb08f46/), [Lund NfL CALD Gene Therapy Molecular Therapy Advances 2026](https://consensus.app/papers/details/35746e04ff4a58eb8b8c03fcf3735d62/)*

*#FDA #GeneTherapy #Oo #JClinicalPharmacology #PlatformAligned #CMCFlexibility #IglesiasLópez #TherapeuticInnovation #RegulatoryScience #CGT #Quality #Manufacturing #Comparability #PotencyAssay #Lund #NfL #CALD #MolecularTherapyAdvances #Biomarker #Prognostic #MRI #LoesScore #TranslatingDay #RegulatoryTranslation #GeneTherapy #OrphanDesignation #ExpeditedPathway*

---

### Post 7: Spatial Transcriptomics — Pan-Cancer TSME 56 LCPs + SCLC Lymph Node Metastasis Atlas

🗺️ **[Spatial Transcriptomics] 12개 암종 373 samples에서 56 LCPs + 13 niches로 TSME 체계적 분석 확인(Li Cell Reports Medicine 2026) + SCLC 75명 600K+ cells lymph node metastasis spatial cellular ecosystem 분석 확인(Zhang Cell Reports Medicine 2026) + Gastric cancer lymphocyte-aggregated region(LAR) + TLS spatial atlas 확인(Gao Nature Communications 2026): spatial transcriptomics의 전이 분석 동시 확인**

Spatial Transcriptomics의**전이 분석**이 출처에서 동시에 확인된다[16][17][18].

**Pan-Cancer TSME: 56 LCPs + 13 Niches + 임상 결과 연관[16]**
Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 12개 암종 373 samples의 spatial transcriptomics를 분석한다. **56 local cellular programs(LCPs) + 13 recurrent niches** 식별. **Niche-shared/niche-specific interactions**: ligand-receptor analysis로 확인. **핵심 발견**: tumor cells와 macrophages의 gene expression이 specific location에 크게 의존. **Niche_4(Macrophage+tumor cells)**: poor prognosis + immunotherapy resistance 연관. **Niche_11(Macrophage+immune cells)**: better survival + treatment response 예측. **临床적 의의**: TSME systematic dissection으로 cellular communication + structural influences 이해深化. 핵심: 12개 암종 373 samples에서 56 LCPs + 13 niches로 TSME 체계적 분석 — 전이 근거 확립.

**SCLC Lymph Node Metastasis: 75명 600K+ Cells Spatial Ecosystem[17]**
Zicheng Zhang et al.(Cell Reports Medicine 2026)의 연구는 SCLC lymph node metastasis의 spatial cellular ecosystem를 분석한다. **105 primary/metastatic lymph node specimens, 75 SCLC patients, 600,000+ cells**. **LNM-enriched malignant subclusters 3개**: distinct metabolic + angiogenic programs. ** Immune exclusion features**: metastatic sites에서 상관관계. **Vascular-immune crosstalk**: endothelial cells가 malignant cells 회피 + cytotoxic T cells와 functional perivascular niches 형성. **PIHs-1(pan-immune hotspot)**: survival independent predictor. **공간적 아키텍처**: mechanistic insights + translatable biomarkers 제공. 핵심: SCLC lymph node metastasis 75명 600K+ cells spatial atlas — 종양 미세환경 전이 분석.

**Gastric Cancer LAR: Lymphocyte-Aggregated Region + TLS Spatial Atlas[18]**
Sen Gao et al.(Nature Communications 2026)의 연구는 gastric cancer의 lymphocyte-aggregated region(LAR)을 분석한다. **4 spatial regions** 식별. **LAR**: lymphocyte aggregates + tertiary lymphoid structures(TLS). **Naive T cell abundance**: T cell activation-associated pathways와 연관. **두 transcriptomically distinct groups(A/B)**: Group A — more activated lymphocytes가 adjacent cancerous regions에, Group B — more resting lymphocytes. **Group A PD1+CD27+ CD8 T cells**: CD70+LAMP3+ dendritic cells와 closer proximity. **면역치료 biomarker**: gastric cancer TME spatial resolution + immunotherapy biomarkers. 핵심: Gastric cancer LAR + TLS spatial atlas — 면역 치료 전이 분석.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Koppensteiner Oncoimmunology**으로 **CAF-T cell adenosine axis로 NSCLC 예후 biomarker**를, **Lang Cancer Biology Therapy**으로 **CD3+ B cells의 DLBCL microenvironment 재구성**을, **Walberg Gut Microbes**으로 **bacterial LPS-CRC immune crosstalk**을 제시했다면, 오늘은 **Li Cell Reports Medicine**으로 **12개 암종 56 LCPs + 13 niches + Niche_4/11 임상 결과 연관**을(체계적 전이 근거), **Zhang Cell Reports Medicine**으로 **SCLC 75명 600K+ cells + PIHs-1 survival predictor**를(전이 분석), **Gao Nature Communications**으로 **gastric cancer LAR + TLS + PD1+CD27+ CD8 T cells proximity**를(면역 치료 biomarker) 동시에 제시한다. Expanding(8/20) → 전이 분석 강화 Translating(8/26).

실무 함의: spatial transcriptomics 연구팀에서 Li et al.의 niche-4/11 분석을 참조하여 immunotherapy resistance strategy를 수립해야 한다.

*출처: [Li Pan-Cancer TSME Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Zhang SCLC Lymph Node Metastasis Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Gao Gastric Cancer LAR Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/)*

*#SpatialTranscriptomics #Li #CellReportsMedicine #TSME #LCPs #Niches #Niche4 #Niche11 #Macrophage #TumorCells #ImmuneCells #Prognosis #Zhang #SCLC #LymphNodeMetastasis #600KCells #PIHs1 #PanImmuneHotspot #Gao #GastricCancer #LAR #TLS #TertiaryLymphoidStructures #PD1 #CD27 #CD8T #TranslatingDay #TranslationalEvidence #SpatialAtlas #ImmunotherapyResistance #Biomarker*

---

### Post 8: 오늘의 요약 — Translating(전이 Day) 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

8/26(Translating)의 핵심: Expanding(8/20)된 기술들이 **실험실 → 임상/산업으로의 전이(Translating) 단계에 진입하는 날**이었다.

**1. PE First-in-Human Functional Restoration(Lushington Molecular Therapy 2026)**: PE first-in-human trial에서 functional restoration + promising safety profile 확인 — prime editing 임상 전이里程碑 달성. [Lushington Molecular Therapy 2026]

**2. Non-Viral CRISPR 136 Trials · 36 In Vivo(Lummerstorfer Drug Delivery 2026)**: viral vectors dominance에서 non-viral vectors로의 명확한 전환(136 trials, 36 in vivo delivery) — 전달 기술 산업 전이. [Lummerstorfer Drug Delivery 2026]

**3. Pharma AI Platforms 2026 Deals 급증(Lin GEN Biotechnology 2026)**: 2026년 pharma companies의 AI platforms 대규모 딜 급증 — AI drug discovery 산업 전이 가속화. [Lin GEN Biotechnology 2026]

**4. ROCKET AlphaFold2 + Cryo-EM/ET/X-ray 통합(Fadini Nature Methods 2026)**: 실험 데이터를 AlphaFold2 prediction에 직접 통합하여 자동 모델링 달성 — computational-experimental 전이. [Fadini Nature Methods 2026]

**5. scFM Attention Co-Expression만 포착(Kendiukhov ArXiv 2026)**: attention patterns가 regulatory signal 아닌 co-expression만 encode 확인 — perturbation prediction 한계로 전이 한계 인식 강화. [Kendiukhov ArXiv 2026]

**6. NfL CALD Gene Therapy 예후 예측 50% 감소(Lund Molecular Therapy Advances 2026)**: NfL biomarker로 gene therapy 후 disease progression 예측 — biomarker-driven regulatory translation. [Lund Molecular Therapy Advances 2026]

**8월 27일 전망**: Translating된 기술들의 임상/산업 전이 속도와 전이 한계 인식이 핵심 변수. 특히 PE first-in-human의 follow-up data, ROCKET의 추가 실험 데이터 통합 사례, NfL biomarker의 다른 gene therapy 적용이 관전.

*출처: [Lushington PE First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Lummerstorfer Non-Viral CRISPR Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/), [Jong Prime Editing BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/), [Lin Pharma AI Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Ali AI Drug Discovery Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/), [Seyhan AI Drug Discovery Critical Reviews 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Fadini ROCKET AlphaFold Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/), [Slanináková AlphaFind v2 NAR 2026](https://consensus.app/papers/details/ab20081f847c53918401f1728031bb64/), [Yin Protein Structure AI Frontiers 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Kendiukhov scFM Interpretability ArXiv 2026](https://consensus.app/papers/details/d53d25b7c73855978a42e9832c85eb8c/), [Yan scFM Learnability BMC Genomics 2026](https://consensus.app/papers/details/db23619e10075c0eb0957368f25ba7de/), [Dimitrov scFM Perturbation Nature Reviews Genetics 2026](https://consensus.app/papers/details/4c9a5a9396a85b9797d6e1f0ecd4286b/), [Oo FDA Gene Therapy J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Iglesias-López CGT Quality Therapeutic Innovation 2026](https://consensus.app/papers/details/49b52f00e1d45031af864f85aeb08f46/), [Lund NfL CALD Molecular Therapy Advances 2026](https://consensus.app/papers/details/35746e04ff4a58eb8b8c03fcf3735d62/), [Li Pan-Cancer TSME Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Zhang SCLC Lymph Node Metastasis Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Gao Gastric Cancer LAR Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/)*

*#TranslatingDay #Summary #Lushington #PE #FirstInHuman #MolecularTherapy #Lummerstorfer #NonViral #CRISPR #136Trials #Lin #PharmaAI #Deals2026 #Ali #Seyhan #Fadini #ROCKET #AlphaFold #CryoEM #Kendiukhov #Attention #scFM #Yan #Learnability #ScalingLaws #Dimitrov #Perturbation #CausalInference #Oo #FDA #GeneTherapy #IglesiasLópez #CGT #Quality #Lund #NfL #CALD #Biomarker #Li #TSME #LCPs #Niches #Zhang #SCLC #PIHs1 #Gao #GastricCancer #LAR #TLS #Translating #Expanding #ClinicalTranslation #IndustrialTranslation*

---

## Sources

[1] [Lushington et al. — A primer on prime: A prime editing update from advances to first-in-human trial. Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/)
[2] [Lummerstorfer et al. — Non-Viral CRISPR carriers: transient delivery with lasting effects. Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/)
[3] [Jong et al. — Prime editing updates: technological evolution, methodological expansion, and delivery strategies for in vivo applications. BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/)
[4] [Lin — Pharma Bets Big on AI Platforms with Flurry of 2026 Deals. GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/)
[5] [Ali et al. — Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation. Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/)
[6] [Seyhan et al. — AI in Drug Discovery and Development. Critical Reviews in Oncology/Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)
[7] [Fadini et al. — AlphaFold as a prior: experimental structure determination conditioned on a pretrained neural network. Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/)
[8] [Slanináková et al. — AlphaFind v2: similarity search in AlphaFold DB and TED domains across structural contexts. Nucleic Acids Research 2026](https://consensus.app/papers/details/ab20081f847c53918401f1728031bb64/)
[9] [Yin et al. — Protein structure prediction powered by artificial intelligence: from biochemical foundations to practical applications. Frontiers in Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)
[10] [Kendiukhov — Systematic Evaluation of Single-Cell Foundation Model Interpretability Reveals Attention Captures Co-Expression Rather Than Unique Regulatory Signal. ArXiv 2026](https://consensus.app/papers/details/d53d25b7c73855978a42e9832c85eb8c/)
[11] [Yan et al. — Evaluating the learnability of single-cell large language models on multiple tasks. BMC Genomics 2026](https://consensus.app/papers/details/db23619e10075c0eb0957368f25ba7de/)
[12] [Dimitrov et al. — Interpretation, extrapolation and perturbation of single cells. Nature Reviews Genetics 2026](https://consensus.app/papers/details/4c9a5a9396a85b9797d6e1f0ecd4286b/)
[13] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)
[14] [Iglesias-López et al. — Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective. Therapeutic Innovation & Regulatory Science 2026](https://consensus.app/papers/details/49b52f00e1d45031af864f85aeb08f46/)
[15] [Lund et al. — CSF and plasma neuro-biomarker dynamics after gene therapy for cerebral adrenoleukodystrophy. Molecular Therapy Advances 2026](https://consensus.app/papers/details/35746e04ff4a58eb8b8c03fcf3735d62/)
[16] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)
[17] [Zhang et al. — Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer. Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)
[18] [Gao et al. — A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region. Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/)